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Background: The HECT family ubiquitin ligase Smurf2 regulates cell polarity, migration, division, differentiation
and death, by targeting diverse substrates that are critical for receptor signaling, cytoskeleton, chromatin
remodeling and transcription. Recent studies suggest that Smurf2 functions as a tumor suppressor in mice.
However, no inactivating mutation of SMURF2 has been reported in human, and information about Smurf2
expression in human cancer remains limited or complicated. Here we demonstrate that Smurf2 expression is
downregulated in human breast cancer tissues, especially of the triple-negative subtype, and address the
mechanism of Smurf2 downregulation in triple-negative breast cancer cells.
Methods: Human breast cancer tissues (47 samples expressing estrogen receptor (ER) and 43 samples with
triple-negative status) were examined by immunohistochemistry for the expression of Smurf2. Ten widely-studied
human breast cancer cell lines were examined for the expression of Smurf2. Furthermore, microRNA-mediated
regulation of Smurf2 was investigated in triple-negative cancer cell lines.
Results: Immunohistochemical analysis showed that benign mammary epithelial cells expressed high levels of
Smurf2, so did cells in ductal carcinomas in situ. In contrast, invasive ductal carcinomas showed focal or diffuse
decrease in Smurf2 expression, which was observed more frequently in triple-negative tumors than in ER-positive
tumors. Consistently, human triple-negative breast cancer cell lines such as BT549, MDA-MB-436, DU-4475 and
MDA-MB-468 cells showed significantly lower expression of Smurf2 protein, compared to ER + or HER2+ cell lines.
Studies using quantitative PCR and specific microRNA inhibitors indicated that increased expression of miR-15a,
miR-15b, miR-16 and miR-128 was involved in Smurf2 downregulation in those triple-negative cancer cell lines,
which have mutations in the retinoblastoma (RB) gene. Forced expression of RB increased levels of Smurf2 protein
with concomitant decreases in the expression of the microRNAs.
Conclusions: This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative
breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference
with Smurf2 translation. The new link from RB inactivation to Smurf2 downregulation is likely to play a role in
malignant phenotypes of triple-negative breast cancer cells.
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Triple-negative breast cancers (TNBCs), which lack the
expression of estrogen receptor (ER) and progesterone
receptor (PR) and the amplification of the HER2 gene,
are a clinically aggressive and molecularly diverse type
of breast cancer [1]. TNBCs constitute 10%–20% of all
breast cancers and highly prevalent in African-American
women [2]. The survival rates of breast cancer patients
have shown a tendency of improvement recently, pos-
sibly owing to targeted therapies against ER/PR-positive
or HER2-positive cancers. Nonetheless, the treatment of
patients with TNBC remains to be a major challenge,
and TNBC is associated with poorer prognosis than
other breast cancer subtypes [3]. A recent study demon-
strated that TNBCs can be categorized into at least six
subgroups based on the gene expression profiles [1].
Profiling the transcriptomes of cancer tissues and cell
lines has significantly advanced our knowledge in the
biology of TNBC and potential therapeutic targets; how-
ever, it remains obscure how posttranscriptional changes
in tumor suppressors or oncoproteins contribute to the
development of TNBC.
Smurf2 is a HECT-family ubiquitin ligase (E3), which
has been implicated in diverse biological functions in-
cluding the transforming growth factor-beta (TGF-β)
signaling, mitotic regulation, cell polarity, motility and
chromatin modifications [4]. According to the literature,
Smurf2 appears to play complex roles in tumorigenesis.
A previous study using immunohistochemistry showed
that esophageal squamous cell carcinomas expressed
high levels of Smurf2, which correlated with poor prog-
nosis [5]. Another study on lung adenocarcinomas and
head & neck carcinomas showed a positive correlation
between Smurf2 protein levels and EGFR protein levels
[6]. In contrast, there have been several reports demon-
strating decreased expression of Smurf2 in other types
of cancer. Protein levels of Smurf2 were found to be
downregulated in human lymphoma and breast cancer
tissues relative to non-cancer tissues [7]. In a study on
prostate cancers, Smurf2 mRNA levels were lower in ad-
vanced tumors compared to less advanced organ-confined
tumors, suggesting association of Smurf2 downregulation
with tumor progression [8]. Importantly, two recent studies
using Smurf2-null mice have shown that Smurf2-deficiency
increases susceptibility to spontaneous tumorigenesis in
various tissues including the liver, lung, pituitary and mam-
mary gland [7,9]. The activity of Smurf2 to ubiquitinate and
degrade RNF20, a RING-family E3 that controls histone
H2B ubiquitination and genome stability, has been impli-
cated for the tumor suppressive role of Smurf2 [7].
In this study we demonstrate that human TNBC tis-
sues express significantly lower levels of Smurf2 protein
relative to normal mammary tissues, ductal carcinomas
in situ (DCIS) and ER+/PR + breast cancer tissues. Wealso have revealed that microRNAs such as miR-15a,
miR-15b, miR-16 and miR-128, whose expression is
increased by inactivating mutations of the retinoblast-
oma (RB) gene, downregulate translation of Smurf2 pro-
tein in TNBC cells. These results suggest that Smurf2
downregulation is an event associated with RB loss and
microRNA deregulation during the progression of
TNBC, and likely involved in the aggressive phenotypes.
Methods
Patients
Surgical specimens were obtained from breast cancer pa-
tients (47 ER+/PR + and 43 TN) who had mastectomy or
lumpectomy at Louisiana State University Health Sci-
ences Center, Shreveport, LA, during the period between
2002 and 2010. This study was reviewed and approved
in advance by the Institutional Review Boards of the
Louisiana State University Health Sciences Center
and the Feinberg School of Medicine, Northwestern
University. All necessary consent was obtained from
every patient involved in the study, including consent
for participation in the study and publication of data.
The patients’ ages ranged from 27 to 96 years, and their
mean age was 54.2 years. Tumor stages were classified
according to the seventh edition of the TNM (tumor-
node-metastasis) classification of breast carcinomas pub-
lished by American Joint Committee on Cancer. The
clinicopathological parameters of the patient cohorts are
shown in Table 1 and Additional file 1: Table S1.
Immunohistochemistry for Smurf2
Immunohistochemical staining of paraffin-embedded hu-
man tissues was performed by the standard avidin-biotin
peroxidase complex method. Paraffin sections were la-
beled and dried in 60°C oven for at least 4 hour, cooled,
deparaffinized, and incubated in antigen retrieval solution
(#H-3300; Vector Laboratories, Burlingame, CA). For anti-
gen retrieval, slides were heated and cooled in antigen re-
trieval solution for 25 and 20 minutes, respectively. Slides
were then rinsed 4–5 times in distilled water; once in 0.3%
peroxide in 50% methanol for 30 minutes, and 3 times for
5 minutes in wash buffer. Subsequently, slides were proc-
essed using the BioGenex i6000 Automated Staining
System. Blocking was conducted by soaking slides in 10%
goat serum in phosphate-buffered saline (PBS), for 15 mi-
nutes, in 5% casein block in PBS for 10 minutes, and in
10% goat serum in PBS for 1 minute. Slides were then
incubated with the primary antibody for Smurf2 (Y-21:
sc-130878, Santa Cruze Biotechnology, CA) at a dilution
of 1:100 in Dako antibody diluent (Dako, Glostrup,
Denmark) for 1 hour, followed by 5 times rinse with wash
buffer. Samples were then incubated with the secondary
(MultiLink-BioGenex Super Sensitive Link-Label IHC
Detection System #QP900-9 L; BioGenex, Fremont, CA)
Table 1 Clinicopathologic characteristics of cohorts of
breast cancers
ER/PR + TN
No. of cases 47 43
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with a horseradish peroxidase solution (BioGenex Super
Sensitive Link-Label IHC Detection System #QP900-9 L)
for 15 minutes. Following triple washes, 3,3-Diaminoben-
zidine (#K3466; DakoCytomation Liquid DAB Subs-
trate Chromogen System) was applied to samples for
5 minutes. Samples were then rinsed 3 times, stained
with hematoxylin (#S3301; DakoCytomation Automation
Hematoxylin) for 2 minutes, and rinsed 3 times again in
wash buffer. Slides were then rinsed with distilled water
for 4 minutes, and dehydrated sequentially with ethanol
and xylene. A negative control to each section was pre-
pared by using normal rabbit serum instead of the primary
antibody. While benign mammary epithelia and ductal
carcinomas in situ (DCIS) displayed uniform strong stain-
ing for Smurf2, invasive carcinomas often exhibited focal
patterns of Smurf2 staining (see Figure 1). To compara-
tively examine decreased expression of Smurf2 in invasive
carcinomas, percentages of Smurf2-positive cells in carcin-
oma regions were scored as follows: 0 (Smurf2+ cells incarcinoma tissues: 0-5%), 1+ (6%-25%), 2+ (25%-50%),
3+ (50%-75%), and 4+ (>75%).
Cell culture and reagents
Human non-transformed mammary epithelial MCF-10A
cells, and 9 human breast cancer cell lines, MCF-9,
T47D, MDA-MB-231, BT549, MDA-MB-436, DU4475,
MDA-MB-468, BT474 and SK-BR-3, were obtained from
American Tissue Culture Collection (ATCC), and cultured
under standard conditions recommended by ATCC. Fetal
bovine sera and calf sera were obtained from HyClone/
Thermo Fisher Scientific (Logan, UT), and media, antibi-
otics and other chemicals were purchased from Corning
Cellgro (Manassas, VA) and GiBCO/Invitrogen (Carlsbad,
CA). Cycloheximide was purchased from Sigma-Aldrich
(St. Louis, MO).
Immunoblotting
Immunoblotting was performed as previously described
[10]. Anti-Smurf2 antibody was obtained from Upstate
Biotechnology (07–249, Lake Placid, NY), and anti-RB
and anti-α-Tubulin antibodies were from BD Pharmingen
(554136, BD Biosciences, San Jose, CA) and Sigma-
Aldrich (T6199), respectively. Target proteins were visual-
ized by enhanced chemiluminescence (Thermo Scientific,
Rockford, lL). The band intensities were quantified by
densitometry using the Photoshop and Image J software
and normalized to those of their respective control bands.
Real time PCR
Total RNA samples were collected using the Trizol
reagent (Invitrogen, Carlsbad, CA). Levels of Smurf2
mRNA were quantified in comparison with those of
GAPDH mRNAs, using the Power SYBR® Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA) and the
Applied Biosystems 7900. Levels of miR-15a, miR-15b,
miR-16 and miR-128 were measured by quantitative
RT-PCR, using miScript PCR system including pre-
designed miRNA-specific primers (Qiagen, Valencia, CA)
and the Applied Biosystems 7900. RNU6-2 was used as
the reference endogenous control, and 2-ΔΔCt method [11]
was used to analyze the relative miRNA expression.
Transfection with plasmids and miRNA inhibitors
Cells were transfected with Ambion® Anti-miR™ miRNA
Inhibitors specifically against miR-15a, miR-15b, miR-16
and miR-128 (Ambion/Invitrogen, Carlsbad, CA), using
the Lipofectamine® RNAiMAX transfection reagent (Invi-
trogen, Carlsbad, CA) according to the manufacturer’s
protocol. The expression vector for green fluorescence pro-
tein (GFP) fused with full length retinoblastoma protein
(RB) and pEGFP-C3 for GFP expression were obtained
from Addgene (Cambridge, MA). Plasmid transfection was
Figure 1 Smurf2 expression is decreased in triple-negative breast cancer tissues. (A) Immunohistochemistry for Smurf2 was conducted using
human mammary tissues including benign mammary epithelia, ductal carcinomas in situ (DCIS), ER+/PR + and triple-negative (TN) invasive carcinomas.
Upper left panel shows x10 magnification, and the other panels show x20 pictures with x40 magnified views. (B) Percent of Smurf2-positive cells in
ER+/PR + (n = 47) and TN (n = 43) breast cancer specimens. To quantify focal loss of Smurf2 expression in carcinoma regions, immunohistochemical
labeling of Smurf2 was scored according to the following five categories: 0 (Smurf2+ cells in carcinoma tissues: 0-5%), 1+ (6%-25%), 2+ (25%-50%),
3+ (50%-75%), and 4+ (>75%). Data are shown as mean + SEM with the p value for statistical significance.
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Invitrogen, according to the manufacturer’s protocol.
Statistical analysis
Immunohistochemical labeling of Smurf2 in carcinoma
tissues was scored as described above and statistically
analyzed using Fisher’s exact test and the Wilcoxon rank
sum test. Other quantified data from immunoblotting
and real time PCR were analyzed using Student’s t test.
P < 0.05 was considered significant.
Results
Smurf2 downregulation in TNBC
To determine whether the expression of Smurf2 protein
was altered in breast cancer tissues, surgical specimens
from 90 breast cancer patients (47 with ER+/PR + cancersand 43 with TNBCs, see Table 1 and Additional file 1:
Table S1) were analyzed by immunohistochemistry for
Smurf2. Regions of benign mammary epithelia and DCIS
showed robust Smurf2 staining both in the cytoplasm and
nucleus (Figure 1A, upper panels). In samples with inva-
sive carcinomas, Smurf2 staining was found decreased
focally or sometimes diffusely, and the downregulation of
Smuf2 was significantly more obvious in TNBCs com-
pared to ER+/PR + cancers (Figure 1A lower panels,
Figure 1B). The median of the Smurf2 staining scores in
TNBCs was 2 (25%-50% of tumor cells were Smurf2-
positive), while that in ER+/PR + cancers was 3 (50%-75%
Smurf2-positive). Higher tumor grades and Ki67 scores
were observed in the TN group, compared with the
ER+/PR + group. Lower Smurf2 staining scores were asso-
ciated with higher tumor grades (p = 0.0004) and higher
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scores (Additional file 1: Table S1). We then examined
human breast cancer cell lines and non-transformed
mammary epithelial MCF-10A cells by immunoblotting
for Smurf2 (Figure 2A). Levels of Smurf2 protein in ER+/
PR + cancer cells (MCF-7 and T47D) and those in HER2+/
ER+/PR + BT474 cells and HER2+/ER-/PR- SK-BR-3 cells
were comparable with Smurf2 levels in MCF-10A cells. In
sharp contrast, Smurf2 protein levels in 4 of 5 TNBC cell
lines, BT549, MDA-MB-436, DU-4475 and MDA-MB-
468 cells, were significantly lower than those in MCF-10A
and the ER+/PR + cell lines. Only MDA-MB-231 cells
showed high levels of Smurf2 expression. To determine
whether Smurf2 downregulation in the TNBC cell lines
resulted from transcriptional repression, Smurf2 mRNA
levels were measured by real time PCR (Figure 2B). In the
four cell lines that exhibited lower levels of Smurf2 pro-
tein, no decreases in the mRNA levels were observed, rela-
tive to that in MCF-10A cells, suggesting that Smurf2 is
downregulated at the posttranscriptional level in those
TNBC cell lines. In contrast, MDA-MB-231 cells exhib-
ited remarkably higher Smurf2 mRNA levels, indicatingFigure 2 Smurf2 protein is downregulated in triple-negative breast ca
mRNA. (A) Immunoblotting for Smurf2 in the following cell lines: MCF-10A
mammary carcinomas with expression of the estrogen and progesterone r
MDA-MB-468, TNBCs; BT474 and SK-BR-3, mammary carcinomas with HER2
in the cancer cell lines to that in MCF-10A cells. The density of each Smurf
are shown as mean + SEM from at least three experiments, and the asterisk
in MCF-10A cells. (B) Real time PCR analysis for Smurf2 mRNA. Data are no
expression levels to that in MCF-10A cells. (C) Degradation of Smurf2 prote
MDA-MB-231 and BT549 cells were treated with 100 μg/ml CHX for the ind
Smurf2 and α-tubulin.that Smurf2 is transcriptionally upregulated only in this
particular cell line. To further examine whether protein
degradation plays a dominant role in determining the
steady-state level of Smurf2 protein, we examined the
stability of Smurf2 in MCF-10A, MDA-MB-231, and
BT549 cells, using the translation inhibitor cycloheximide
(Figure 2C). According to the decay of Smurf2 levels in
the presence of cycloheximide, the half-life of Smurf2 in
MCF-10A cells was determined to be about 8 hours. Inter-
estingly, the half-life of Smurf2 in MDA-MB-231 cells was
less than 3 hours, suggesting that Smurf2 protein is ra-
ther more unstable in this cell line that overexpresses
its mRNA. On the other hand, Smurf2 protein was more
stable in BT549 cells, displaying a half-life of more than
12 hours. Taken together, these data indicated that the
expression of Smurf2 protein is downregulated fre-
quently in human TNBC tissues, and similar downregu-
lation was observed in four of the five TNBC cell
lines examined here. MDA-MB-231 cells exceptionally
showed transcriptional upregulation of Smurf2, which
appeared to be counteracted by enhanced degradation
of the protein.ncer (TNBC) cell lines without concomitant decreases in Smurf2
, untransformed human mammary epithelial cells; MCF-7 and T47D,
eceptors (ER+/PR+); MDA-MB-231, BT549, MDA-MB-436, DU4475 and
amplification. The bar graph indicates relative levels for Smurf2 protein
2 signal on immunoblots was normalized by that of α-tubulin. Data
s indicate statistically significant (p < 0.05) differences from the level
rmalized by signals for GAPDH mRNA, and presented as relative
in assessed by treatment with cycloheximide (CHX). MCA-10A,
icated hours, and lysates were analyzed by immunoblotting for
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Deregulation of microRNAs (miRNAs) has been impli-
cated to the biology of breast cancer such as estrogen
signaling, migration and metastasis [12,13]. We hypothe-
sized that some miRNAs were involved in the post-
transcriptional downregulation of Smurf2 in TNBC, and
used multiple online databases such as TargetScan and
PicTar to identify miRNAs that potentially bind to
Smurf2 mRNAs. The analysis led us to candidates such
as miR-128 (binding to Smurf2 3′UTR, 5′-CACU-
GUGA-3′) and the miR-15 family miRNAs including
miR-15a, miR-15b and miR-16 (binding to Smurf2 3′
UTR, 5′-GCUGCUA-3′). The miR-15 family and miR-
128 have been implicated for the regulatory network in
breast cancer initiating cells [14,15]. Thus, we measured
the expression of miR-15a, miR-15b, miR-16 and miR-
128b in the breast cancer cell lines (Figure 3). DU4475
cells showed increased expression of miR-15b, miR-16
and miR-128, relative to their expression in MCF-10A
cells. BT549 cells exhibited increased expression of
miR-15a, miR-15b and miR-16. MDA-MB-436 cells had
increased expression of miR-15b, miR-16, and miR-128.
Thus, these TNBC cell lines that exhibited Smurf2Figure 3 Expression levels of miR-15a, miR-15b, miR-16 and miR-128
determined by real time PCR in the following cell lines: MCF-10A, untransfo
with expression of the estrogen receptor (ER+); MDA-MB-231, BT549, MDA-
normalized by signals for RNU6-2 as controls, and presented as relative exp
from 3–5 experiments, and the asterisk indicates statistically higher (p < 0.0
MCF-10A cells.downregulation had a tendency to express higher levels
of these miRNAs. In contrast, MDA-MB-231 cells,
which had high levels of Smurf2 mRNA and protein,
showed no major change in the expression of these miR-
NAs, except for a decrease in miR-15a. Also in MCF-7
cells, the levels of miR-15a, miR-15b and miR16 were
low, whereas the expression of miR-128 was modestly
higher. To further delineate the role of the miRNAs in
Smurf2 downregulation observed in BT549, MDA-MB-
436 and DU4475 cells, cells were transfected with
miRNA inhibitors (antagomirs) against miR-15a, miR-
15b, miR-16 or miR-128 (Figure 4). Treatment with
these antagomirs resulted in substantial increases in
Smurf2 protein levels in the TNBC cell lines, suggesting
the involvement of these miRNAs in downregulating
Smurf2 in TNBC.
Linkage of RB mutations to miRNA deregulation and
Smurf2 downregulation
A recent study demonstrated that miR-15 and miR-16
are direct targets of the E2F transcription factors [16]. A
number of TNBCs have inactivating mutations of the
retinoblastoma tumor suppressor gene (RB) [17], whichin breast cancer cell lines. Levels of the indicated microRNAs were
rmed human mammary epithelial cells; MCF-7, mammary carcinomas
MB-436, and DU4475, triple-negative mammary carcinomas. Data are
ression levels to that in MCF-10A cells as 1.0. The bars indicate S.E.M.
5) levels of each miRNA in the particular cell line than in
Figure 4 MicroRNAs such as miR-15, miR-16 and miR-128 are involved in downregulation of Smurf2 protein in triple-negative breast
cancer. Human triple-negative breast cancer cell lines, BT549, MDA-MB-436 and DU4475 cells, were transfected with microRNA inhibitors against miR-15a,
miR-15b, miR-16 and miR-128, or nonspecific ssRNA as negative control (NC), and cellular levels of Smurf2 protein were determined at 24 h (A, B) or 48 h
(C) post-transfection by immunoblotting. The density of each Smurf2 signal on immunoblots was normalized by that of α-tubulin, and presented as relative
expression levels to that in negative control (NC) as 1.0. Quantified data on bar graphs show means + SEM from three experiments, and the asterisks
indicate statistically significant (p < 0.05) differences from negative control (NC).
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pothesized that RB inactivation could result in elevated
expression of the miR-15 family and possibly miR-128,
which contributed to the downregulation of Smurf2.
Immunoblotting for RB demonstrated that all four TNBC
cell lines that exhibited Smurf2 downregulation had no
detectable expression of RB (Figure 5A). In contrast,
MDA-MB-231 cells, which expressed high levels of
Smurf2, showed robust RB expression comparable to that
in MCF-7 and T47D cells. This RB expression patterns are
consistent with the genotypes of the RB gene in these cell
lines as summarized in [1]. To further examine the role of
RB in the regulation of Smurf2, we transfected BT549 cells
with an expression vector for the full-length RB protein
fused with green fluorescence protein (GFP) (Figure 5B).
Forced expression of GFP-RB resulted in a significant in-
crease in cellular levels of Smurf2 protein, accompanied
by substantial decreases in the expression of miR-15a,
miR-15b, miR-16 and miR-128b (Figure 5C). These results
indicate that forced expression of RB in TNBC cells with
RB mutations could restore levels of Smurf2 protein ex-
pression, suggesting the significance of the RB-miRNA
pathway in the control of Smurf2 in TNBC.Discussion
Here we present evidence that the expression of Smurf2
protein is downregulated preferentially in TNBC. The
cancer-associated downregulation is consistent with the
recent studies that suggested the tumor suppressive
function of this E3 enzyme [7,9]. Low expression of
Smurf2 protein was also observed in several TNBC cell
lines, which had RB mutations and high expression of
miR-15a, miR-15b, miR-16 and miR-128. Antagomirs
against these miRNAs substantially increased Smurf2
levels in the TNBC cell lines. Moreover, forced expres-
sion of RB in the TNBC cells increased cellular levels of
Smurf2, with concomitant decreases in the expression of
those miRNAs. Therefore, RB inactivation accounts at
least partly for Smurf2 downregulation in the TNBC
cells, via deregulated expression of the miR-15 family
and miR-128.
Recent progress in the field has indicated that numer-
ous miRNAs play major roles in breast cancer biology,
from tumor initiation to metastasis [13]. Our finding
that miR-15/16 and miR-128 are involved in Smurf2
downregulation in TNBC provides a new pathway to the
miRNA-mediated biological processes in breast cancer.
Figure 5 The loss of the retinoblastoma tumor suppressor (RB) expression plays a role in Smurf2 downregulation in triple-negative
breast cancer (TNBC) cells, via upregulation of miR-15, miR-16 and miR-128. (A) Immunoblotting for RB protein in the indicated TNBC cell
lines. (B) Increased expression of Smurf2 by forced expression of RB in RB-null BT549 cells. Cells were transfected with an expression vector for a
green fluorescence protein (GFP)-RB fusion protein, a vector for GFP, or an empty vector (pcDNA3.1). Levels of Smurf2 and RB were determined
at 42 h post-transfection by immunoblotting. The bar graph indicates relative levels for Smurf2 protein normalized by those for α-tubulin, shown
as means + SEM from three experiments. The asterisk indicates statistical significance (p < 0.05). (C) Decreased expression of miR-15a, miR-15b,
miR-16 and miR-128 in BT549 cells transfected with the GFP-RB vector. Levels of the indicated microRNAs were determined by real time PCR.
Data are normalized by signals for RNU6-2 as controls, and presented as relative expression levels to that in cells transfected with an empty
vector as 1.0. The bars indicate S.E.M. from three experiments, and the asterisk indicates statistical significance (p < 0.05).
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are direct transcriptional targets of E2F-1, and these
miRNAs in turn restrict E2F activities [16,19]. Whereas
deletion of miR-15a and miR-16 was reported in some
non-small cell lung cancers [19], miRNA expression pro-
filing in human breast cancer subtypes showed that
basal-like TNBCs expressed higher levels of miR-15b
than other subtypes [20]. This is consistent with our
data on the TNBC cell lines. High expression of miR-
128 has been associated with poor prognosis of ER +
breast cancer [21]. miR-128 is known to target Bmi1, the
polycomb transcription factor required for stemness
[15,22], and miR-128 expression may be increased dur-
ing the transition from the cancer-initiating cell state to
the expansive state of breast cancer. Interestingly, onco-
genic p53(R175H) mutant induces the transcription of
miR-128, which then promotes chemoresistance of non-
small cell lung cancer [23], presenting another example
of high miR-128 expression associated with malignant
phenotypes.
Smurf2 is known to be a negative regulator of the TGF-β
signaling, as the Smurf2-Smad7 complex ubiquitinates
the type I TGF-β receptor and the Smad-associated
co-repressor SnoN, targeting them to proteasomal degrad-
ation [24,25]. It is now recognized that the TGF-β signaling
plays dual roles in the development of breast cancer
[26,27]. At the phase of tumor initiation TGF-β functions
as a tumor suppressor, inhibiting cell cycle progressionduring transformation. In contrast, at the late phase of
tumor progression TGF-β promotes invasion and metasta-
sis of breast cancer. The cellular context of cancer, in con-
cert with tumor microenvironment, seems to determine
the responses to TGF-β signaling, while the exact molecu-
lar mechanisms behind the functional transition remain to
be elucidated. The downregulation of Smurf2 protein ob-
served in TNBC may contribute to enhanced TGF-β sig-
naling leading to tumor invasion, epithelial-mesenchymal
transition and metastasis. Besides the TGF-β signaling
components, Smurf2 interacts with a diverse array of pro-
teins, some of which affect tumorigenesis. For example,
Smurf2 interacts with MDM2/HDM2 and enhances its
ability to ubiquitinate and degrade the tumor suppressor
p53 [28], implying that Smurf2 could promote tumorigen-
esis in some context. On the other hand, Smurf2 targets
the helix-loop-helix transcription regulator Id1 (inhibitor
of differentiation or DNA binding) for proteasomal degrad-
ation [29]. Id1 plays oncogenic roles in inhibiting cellular
senescence and maintaining stemness and also in tumor
re-initiation during breast cancer metastasis to the lung
[30,31]. Many of basal-like TNBCs have loss-of-function
mutations in the RB gene [17], which may enhance the Id1
functions by downregulating Smurf2. It should be noted
that MDA-MB-231 cells, which are TNBC with intact RB
function, express markedly high levels of Smurf2 mRNA
and modestly increased levels of the protein with rapid
turn-over. It has been controversial whether Smurf2
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[32,33]. Our study suggests that among widely-used TNBC
cell lines, MDA-MB-231 cells are unique with regard to
Smurf2 regulation and perhaps its role in tumor progres-
sion. The exact impact of Smurf2 downregulation on
the development of RB-deficient TNBC awaits further
investigations.
Increased susceptibility of Smurf2-null mice to spon-
taneous tumorigenesis has provided key evidence for the
tumor suppressive actions of Smurf2 [7,9]. Lymphomas
and hepatocellular carcinomas are tumor types most
commonly observed in two independent strains of
Smurf2-null mice, while a few percent of Smurf2-null
mice develop mammary carcinomas [7]. Smurf2-null
mouse embryonic fibroblasts (MEFs) exhibit impaired
senescence responses, and undergo spontaneous trans-
formation more frequently in culture. Genomic instabil-
ity has been observed in Smurf2-null MEFs, together
with chromatin compaction associated with increased
ubiquitination of histone H2B. These changes seem to
be linked with stabilization of the histone ubiquitin lig-
ase RNF20, as Smurf2 usually promotes degradation of
RNF20 [7]. Smurf2-deficiency may also result in im-
paired mitotic regulation and subsequent genomic in-
stability, as demonstrated in several human cancer cell
lines with siRNA-mediated silencing of Smurf2 [10].
Taken together, downregulation of Smurf2 in TNBCs
with RB mutations could contribute to the malignant
phenotypes at multiple levels. Our ongoing study for un-
defined tumor-suppressive targets of Smurf2 is expected
to provide not only novel insight into the biology of
TNBC but also candidates for therapeutic targets against
this aggressive cancer.
Conclusions
The present study shows that the HECT-family ubiquitin
ligase Smurf2 is downregulated at the posttranscriptional
level in many TNBC cells. miRNAs such as miR-15/16
and miR-128, whose upregulation is linked to the inacti-
vation of RB, play important roles in the downregulation
of Smurf2. The involvement of Smurf2 in cancer devel-
opment has been controversial. The new link from RB
inactivation to Smurf2 downregulation provides novel
insight into the biology of TNBC and potential thera-
peutic strategies.
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